ZAI LAB LTD0000006 Market Cap ($1.82 Billion)
Market Cap & Net Worth: ZAI LAB LTD0000006 (1ZLB)
ZAI LAB LTD0000006 market cap. ZAI LAB LTD0000006 (F:1ZLB) has a market capitalization of $1.82 Billion (€1.56 Billion) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #6259 globally and #954 in its home market, demonstrating a -4.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ZAI LAB LTD0000006's stock price €1.94 by its total outstanding shares 1123537460 (1.12 Billion). Also see 1ZLB cash flow metrics for how efficiently the company converts equity into cash flow.
ZAI LAB LTD0000006 Market Cap History (2020–2026)
ZAI LAB LTD0000006 market cap history from 2020 to 2026. Data shows change from $133.98 Billion to $2.55 Billion (-44.66% CAGR). Check 1ZLB share price today for real-time trading data and today's change.
ZAI LAB LTD0000006 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ZAI LAB LTD0000006's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ZAI LAB LTD0000006 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.20x
ZAI LAB LTD0000006's market cap is 4.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $70.93 Billion | $144.31 Million | -$704.47 Million | 491.51x | N/A |
| 2022 | $3.70 Billion | $215.04 Million | -$443.29 Million | 17.23x | N/A |
| 2023 | $3.42 Billion | $266.72 Million | -$334.62 Million | 12.80x | N/A |
| 2024 | $3.21 Billion | $398.99 Million | -$257.10 Million | 8.03x | N/A |
| 2025 | $1.93 Billion | $460.16 Million | -$175.54 Million | 4.20x | N/A |
Competitor Companies of 1ZLB by Market Capitalization
Companies near ZAI LAB LTD0000006 in the global market cap rankings as of November 4, 2026. Also see ZAI LAB LTD0000006 total assets for a full breakdown of the balance sheet.
Key companies related to ZAI LAB LTD0000006 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ZAI LAB LTD0000006 (2020–2026)
Market capitalization of ZAI LAB LTD0000006 from 2020 to today. Between 2020 and today, ZAI LAB LTD0000006's market cap moved from $133.98 Billion to $ 2.55 Billion, with a yearly change of -44.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.55 Billion | +31.97% |
| 2025 | €1.93 Billion | -39.75% |
| 2024 | €3.21 Billion | -6.15% |
| 2023 | €3.42 Billion | -7.80% |
| 2022 | €3.70 Billion | -94.78% |
| 2021 | €70.93 Billion | -47.06% |
| 2020 | €133.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ZAI LAB LTD0000006 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.82 Billion USD |
| MoneyControl | $1.82 Billion USD |
| MarketWatch | $1.82 Billion USD |
| marketcap.company | $1.82 Billion USD |
| Reuters | $1.82 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more